Mandatory notification of trade
Gentian Diagnostics ASA (GENT) · publisert 29. mai 2026 kl. 13:32 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Matti Heinonen | CEO | Kjøp | 5 000 | 35,8455 NOK | 29. mai 2026 | NO0010748866 | XOSL- Oslo Børs |
Vedlegg
- 2026 05 29 Heinonen notification.pdf (application/pdf, originaldokument)
Meldingstekst
Moss, 29 May 2026
Gentian Diagnostics ASA ("Gentian") has today been notified that the following transaction has been completed by a primary insider in Gentian:
Matti Heinonen, Chief Executive Officer and primary insider in Gentian, has purchased 5,000 shares in Gentian at NOK 35.85 per share. Mr. Heinonen owns 15,569 shares and 100,000 options after this transaction.
PDMR notification pursuant to the EU Market Abuse Regulation Article 19 is attached.
This information is subject to the disclosure requirements pursuant to Section 5-12 of the Norwegian Securities Trading Act, EU Market Abuse Regulation Article 19 and Euronext Oslo Rule Book II.
For further information, please contact: Njaal Kind, Group CFO, njaal.kind@gentian.no, +47 91 90 65 25